| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1432-2277.2012.01544.X |
| P698 | PubMed publication ID | 22897111 |
| P2093 | author name string | Elke Wühl | |
| Gerhard Opelz | |||
| Burkhard Tönshoff | |||
| Rüdiger Waldherr | |||
| Caner Süsal | |||
| Heiko Billing | |||
| Susanne Rieger | |||
| P2860 | cites work | Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause | Q43580802 |
| P433 | issue | 11 | |
| P921 | main subject | rituximab | Q412323 |
| P304 | page(s) | 1165-1173 | |
| P577 | publication date | 2012-08-17 | |
| P1433 | published in | Transplant International | Q15762140 |
| P1476 | title | IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up | |
| P478 | volume | 25 |
| Q47292306 | A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection |
| Q42922850 | A clinical and pathological variant of acute transplant glomerulopathy |
| Q42739167 | A physician survey reveals differences in management of idiopathic pulmonary hemosiderosis |
| Q38215262 | Acute and chronic antibody-mediated rejection in pediatric kidney transplantation |
| Q47773036 | Antibody-mediated rejection in young kidney transplant recipients: the dilemma of noncompliance and insufficient immunosuppression |
| Q87395286 | Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients |
| Q27009997 | Biologics in renal transplantation |
| Q33584895 | Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial |
| Q34761336 | Challenges in pediatric renal transplantation |
| Q60912291 | Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial |
| Q41758257 | Clinical outcome in patients with chronic antibody-mediated rejection treated with and without rituximab and intravenous immunoglobulin combination therapy. |
| Q30279164 | Differential Effects of Tacrolimus versus Sirolimus on the Proliferation, Activation and Differentiation of Human B Cells |
| Q90093164 | Genetic Engineering of the Kidney to Permanently Silence MHC Transcripts During ex vivo Organ Perfusion |
| Q27023312 | Issues in solid-organ transplantation in children: translational research from bench to bedside. |
| Q38243597 | Management of proteinuria in the transplanted patient |
| Q38674466 | Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation |
| Q57474736 | Rituximab, plasma exchange and immunoglobulins: an ineffective treatment for chronic active antibody-mediated rejection |
| Q37704938 | The effect of combination therapy with rituximab and intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients. |
| Q92899718 | The therapeutic challenge of late antibody-mediated kidney allograft rejection |
| Q50063069 | Transplant glomerulopathy |
| Q41967328 | Treatment of Antibody-Mediated Renal Allograft Rejection: Improving Step by Step |
| Q92450432 | Treatment of chronic active antibody-mediated rejection in renal transplant recipients - a single center retrospective study |
| Q65000602 | Treatment with intravenous immunoglobulins and methylprednisolone may significantly decrease loss of renal function in chronic-active antibody-mediated rejection. |
| Q58754949 | Treatment with plasmapheresis, immunoglobulins and rituximab for chronic-active antibody-mediated rejection in kidney transplantation: Clinical, immunological and pathological results |
Search more.